<DOC>
	<DOCNO>NCT01004965</DOCNO>
	<brief_summary>This research study look bone marrow blood sample patient untreated acute myeloid leukemia acute lymphoblastic leukemia enrol clinical trial CALGB-9621 , CALGB-9720 , CALGB 19808 , CALGB 10201 . Studying sample bone marrow blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment .</brief_summary>
	<brief_title>Study Bone Marrow Blood Samples Patients With Untreated Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Enrolled Clinical Trial CALGB-9621 CALGB-9720</brief_title>
	<detailed_description>OBJECTIVES : I . Determine Pgp antigen expression Pgp-mediated functional multidrug resistance ( MDR ) pretreatment acute myeloid leukemia ( AML ) cell adult patient enrol CALGB clinical trial PSC-833 Pgp modulation . II . Correlate Pgp-mediated MDR patient pretreatment characteristic include age , immunophenotype , karyotype . III . Correlate Pgp expression , function , vitro modulation PSC-833 treatment outcome previously untreated AML patient treat CALGB Pgp modulation trial . IV . Determine Pgp expression function AML cell patient refractory relapse leukemia follow induction chemotherapy administer without PSC-833 . V. Correlate acquisition drug resistance change expression antigen gain loss leukemic population relapse patient . VI . Determine role mediator , include multidrug resistance-associated protein ( MRP ) lung-resistance protein ( LRP ) , mediate MDR patient diagnosis relapse refractory disease induction chemotherapy without PSC-833 . VII . Determine frequency Pgp- , MRP- , LRP- mediate MDR adult acute lymphoblastic leukemia cell correlate frequency pretreatment characteristic treatment outcome patient . OUTLINE : Samples obtain : 1 ) pretreatment , 2 ) time documentation refractory disease acute myeloid leukemia ( AML ) patient achieve complete response ( CR ) induction therapy , 3 ) time first relapse patient achieve CR . Marrow cell preferentially use sample , peripheral blood acceptable marrow available blood contains 20 % blast . Pgp expression measure use flow cytometry . AML sample analyze immunoenzyme technique ( IET ) use antibody CD33 , CD34 , MRK16 . B-lineage acute lymphoblastic leukemia ( ALL ) sample analyze IET use antibody CD19 , CD34 , MRK16 . The antibody use analyze T-cells include CD7 CD34 . Pgp function measure grow cell presence PSC-833 vitro measure Pgp expression . Multidrug resistance-associated protein ( MRP ) measure use IET MRPm6 antibody . Lung-resistance protein ( LRP ) measure IET LRP56 antibody . These result correlate flow cytometry result .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Previously untreated patient eligible registered CALGB multidrug resistance modulation treatment protocol acute myeloid leukemia ( CALGB 9621 , CALGB9720 , CALGB19808 , CALGB 10201 ) OR protocols previously untreated acute lymphocytic leukemia Performance status : specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>